Published Online: Monday, March 1, 2004

Roche (Nutley, NJ) recently announced that the FDA has approved labeling for use of the prescription weight-loss medication Xenical (orlistat) in the management of obese adolescents aged 12 to 16 years. This approval offers physicians and parents of overweight and obese adolescents a safe and effective treatment option to help manage their weight. Xenical works locally in the stomach to prevent dietary fat absorption by approximately 30%. It helps the patient lose weight as well as maintain the weight loss. For more information, visit www.xenical.com.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues